Document:

Exhibit 10.33

 

Amended and Restated Change of Control
Retention and Severance Agreement

 

This Amended and Restated Change of Control Retention
and Severance Agreement (the “Agreement”) is made and entered into as of May 18, 2004
(the “Effective Date”),
by and between Cepheid and Russel Enns (the “Executive”) and amends and restates in
its entirety any Change of Control Retention and Severance Agreement by and
between Cepheid and Executive existing prior to the date hereof.  Capitalized terms used in this Agreement
shall have the meanings set forth in Section 3 below.

 

1.             Purpose. 
The purpose of this Agreement is to encourage Executive to remain in the
employ of the Company and to continue to devote Executive’s full attention to
the success of the Company in the event of a Change of Control, as such term is
defined in Section 3 of this Agreement.

 

2.             Termination Upon Change of
Control.  In the event of
Executive’s Termination Upon a Change of Control, Executive shall receive the
following payments and benefits:

 

2.1         Accrued Salary and Vacation, and
Benefits.  Executive shall receive
all salary and accrued vacation (less applicable withholding) earned through
Executive’s termination date, and the benefits, if any, under Company benefit
plans to which Executive may be entitled pursuant to the terms of such plans.

 

2.2         Stock Award Acceleration.                Provided that Executive complies
with Section 5 below, all outstanding stock options granted and restricted
stock issued by the Company to Executive prior to the Change of Control shall
become fully vested and exercisable immediately prior to the effective date of
the Termination Upon a Change of Control.

 

2.3         Cash Severance Payment.  Provided that Executive complies with
Section 5 below, Executive shall receive a lump sum cash payment in an amount
equal to fifteen (15) months of Executive’s the effective base salary (less
applicable withholding), paid within ten (10) business days of the effective
date of the Termination Upon a Change of Control.

 

3.             Definitions.  Capitalized terms used in this
Agreement shall have the meanings set forth in this Section 3.

 

3.1         “Cause” means Executive’s (a)
failure to perform any reasonable and lawful duty of Executive’s position or
failure to follow the lawful written directions of the Chief Executive Officer;
(b) commission of an act that constitutes misconduct and is injurious to the
Company or any subsidiary; (c) conviction of, or pleading “guilty” or “no
contest” to, a felony under the laws of the United States or any state thereof;
(d) committing an act of fraud against, or the misappropriation of property
belonging to, the Company or any subsidiary; (e) commission of an act of
dishonesty in connection with Executive’s responsibilities as an employee and
affecting the business or affairs of the Company; (f) breach of any
confidentiality, proprietary information

 

 

or other agreement
between Executive and the Company or any subsidiary; or (g) failure or refusal
to carry out the reasonable directives of the Company.

 

3.2         “Change of Control” means (a)
any “person” (as such term is used in Sections 13(d) and 14(d) of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”)), other than a trustee or
other fiduciary holding securities of the Company under an employee benefit
plan of the Company, becomes the “beneficial owner” (as defined in Rule 13d-3
promulgated under the Exchange Act), directly or indirectly, of securities of
the Company representing 50% or more of (A) the outstanding shares of
common stock of the Company or (B) the combined voting power of the Company’s
then outstanding securities; (b) the Company is party to a merger or
consolidation which results in the voting securities of the Company outstanding
immediately prior thereto failing to continue to represent (either by remaining
outstanding or by being converted into voting securities of the surviving or
another entity) at least fifty (50%) percent of the combined voting power of
the voting securities of the Company or such surviving or other entity
outstanding immediately after such merger or consolidation; (c) the sale or
disposition of all or substantially all of the Company’s assets (or
consummation of any transaction having similar effect); or (d) the dissolution
or liquidation of the Company.

 

3.3           “Company” means Cepheid and
any successor or assign to substantially all the business and/or assets of
Cepheid.

 

3.4           “Diminution of Responsibilities”
means the occurrence of any of the following conditions, without Executive’s
consent: (a) a significant diminution in the nature or scope of Executive’s
authority, title, function or duties from Executive’s authority, title,
function or duties in effect immediately preceding any Change of Control; (b) a
ten percent (10%) reduction in Executive’s base salary or a twenty-five percent
(25%) reduction in Executive’s target bonus opportunity, if any, in effect
immediately preceding any Change of Control (in either case, unless such
reduction is part of a Company officer-wide program to reduce expenses); (c)
the Company’s requiring Executive to be based at any office or location more
than 50 miles from the office where Executive was employed immediately
preceding the Change of Control; (d) any material breach of the terms of  this Agreement by the Company; or (e)
failure of any successor or assignee to the Company to assume this Agreement.

 

3.5           “Termination
Upon Change of Control” means:

 

(a)           any involuntary termination of the
employment of Executive by the Company without Cause within twelve (12) months
following a Change of Control; or

 

(b)           any resignation by Executive based on
a Diminution of Responsibilities where (i) such Diminution of Responsibilities
occurs within twelve (12) months following the Change of Control, and (ii) such
resignation occurs within ninety (90) days following such Diminution of
Responsibilities.

 

4.             Federal Excise Tax.  If the payments and benefits provided for in this Agreement
constitute “parachute payments” within the meaning of the Internal Revenue Code
of 1986, as amended (the “Code”),
but for this Section 4, would be subject to the excise tax imposed by Section
4999 of the Code, then the payments and benefits under this Agreement will be
payable,

 

 

at Executive’s election,
either in full or in such lesser amount as would result, after taking into account
the applicable federal, state and local income taxes and excise tax imposed by
Section 4999 of the Code, in Executive’s receipt on an after-tax basis of the
greatest amount of benefits.

 

5.             Release of Claims.  The Company may condition the payments and benefits set forth in
Sections 2.2 and 2.3 of this Agreement upon the delivery by Executive of a
signed release of claims in a form satisfactory to the Company.

 

6.             Agreement Not to Solicit.  If Company performs its obligations to
deliver the severance compensation set forth in Sections 2.2 and 2.3 of this
Agreement, then for a period of one (1) year after Executive’s termination of
employment, Executive will not solicit any employee of the Company to
discontinue that person’s employment relationship with the Company.

 

7.             Arbitration.  Any claim, dispute or controversy arising
out of this Agreement, the interpretation, validity or enforceability of this
Agreement or the alleged breach thereof shall be submitted by the parties to
binding arbitration by the American Arbitration Association.  The site of the arbitration proceeding shall
be in Santa Clara County, California, or another location mutually agreed to by
the parties.

 

8.             Conflict
in Benefits; Effect of Agreement.  This Agreement shall supersede all prior arrangements, whether
written or oral, and understandings regarding severance compensation following
a Change of Control and shall be the exclusive agreement for the determination
of any severance compensation due upon Executive’s termination of employment
upon a Change of Control.

 

9.                                       Miscellaneous.

 

9.1           Successors of the Company.  The Company will require any successor or
assign (whether direct or indirect, by purchase, merger, consolidation or
otherwise) to all or substantially all of the business and/or assets of the
Company, expressly, absolutely and unconditionally to assume and agree to
perform this Agreement in the same manner and to the same extent that the
Company would be required to perform it if no such succession or assignment had
taken place.

 

9.2           No
Employment Agreement.  This
Agreement does not alter Executive’s at-will employment status or obligate the
Company to continue to employ Executive for any specific period of time, or in
any specific role or geographic location.

 

9.3           Modification of Agreement.               This Agreement may be modified,
amended or superceded only by a written agreement signed by Executive and the
Chief Executive Officer.

 

9.4           Governing Law.  This Agreement shall be interpreted in
accordance with and governed by the laws of the State of California.

 

9.5           Entire Agreement.  This Agreement constitutes the entire
agreement and understanding of the parties with respect to the subject matter
of this Agreement, and supersedes all prior understandings and agreements,
whether oral or written between or among the parties hereto with respect to the
specific subject matter hereof.

 

 

	
  EXECUTIVE

  	
  CEPHEID

  
	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Russel Enns

  	
  Name:

  	
  John Bishop

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Title:

  	
  Chief
  Executive Officer

  	
   

  
						

 

 

[Signature Page to Amended and Restated Change
of Control Retention and Severance Agreement]Exhibit 10.38

 

FIFTH AMENDMENT TO CREDIT AND
SECURITY AGREEMENT AND WAIVER

 

This FIFTH AMENDMENT TO CREDIT AND SECURITY AGREEMENT AND
WAIVER (this “Amendment”), dated as of June 15, 2004, is by and
among Option Care, Inc., a Delaware corporation (“Option Care”) and its
domestic subsidiaries party hereto (collectively with Option Care, the
“Borrowers”), JPMorgan Chase Bank and LaSalle Bank National Association, as
Lenders (the “Lenders”) and JPMorgan Chase Bank, as administrative and
collateral agent (the “Agent”).

 

W I T N E S S E T H :

 

WHEREAS, the Borrowers, JPMorgan Chase Bank, LaSalle Bank
National Association, Webster Bank and the Agent are parties to that certain
Credit and Security Agreement, dated as of March 29, 2002 (as amended from time
to time, the “Credit Agreement”);

 

WHEREAS, pursuant to an Assignment and Acceptance between
JPMorgan Chase Bank and Webster Bank dated as of the date hereof (the “Webster
Assignment”), JPMorgan Chase Bank is acquiring all right, title and
interest of Webster Bank in and to the Loans and the Revolving Credit
Commitment of Webster Bank;

 

WHEREAS, the Borrowers have requested that the Lenders amend
the Credit Agreement to, among other things, reduce the aggregate amount of the
Revolving Credit Commitments to $20,000,000;

 

WHEREAS, the Borrowers have informed the Agent that pursuant
an Asset Purchase Agreement dated as of May 25, 2004, Option Care Enterprises,
Inc. sold all of the assets used in the clinical trial business conducted by
Clinical Resource Network, Inc. a Delaware corporation and subsidiary of Option
Care Enterprises, Inc., (“Clinical Resource Network”), to ClinTec
Pharmaceuticals Support Services, Inc. (such sale, the “Clinical Resource
Sale”), in exchange for a Non-Recourse Note issued on May 25, 2004 by ClinTec
Pharmaceutical Support Services, Inc. to Option Care Enterprises, Inc. in the
original principal amount of $164,000 (such note, the “Clinical Resource
Promissory Note”); and

 

WHEREAS, the Agent and the Lenders have agreed to amend the
Credit Agreement on the terms and subject to the conditions provided herein;

 

NOW, THEREFORE, in consideration of the premises and the
mutual agreements contained in this Amendment, the Borrowers, the Lenders and
the Agent hereby agree as follows:

 

1.             Capitalized Terms.  Capitalized terms used herein shall have the
meanings set forth in the Credit Agreement.

 

2.             Amendment to Definition of
Applicable Commitment Fee Rate. 
Effective as of June 1, 2004, the definition of Applicable Commitment
Fee Rate set forth in Section 1.01 of the Credit Agreement is hereby amended by
deleting such definition in its entirety and replacing it with the following:

 

“Applicable Commitment
Fee Rate” means a rate of interest per year equal to thirty-seven and one
half (37.5) basis points.  Anything in
this Agreement to the contrary notwithstanding, after the occurrence and during
the continuance of any Event of Default, the Applicable Commitment Fee Rate
shall equal forty-five (45) basis points.”

 

3.             Amendment to Definition of Fixed
Charge Coverage Ratio.  The
definition of “Fixed Charge Coverage Ratio” set forth in Section 1.01 of the
Credit Agreement is hereby amended by deleting such definition in its entirety
and replacing it with the following:

 

1

 

“Fixed Charge Coverage Ratio” means, as of any date,
the ratio of (a) (i) EBITDA of the Borrowers and their Subsidiaries for the
period of four Fiscal Quarters most recently ended prior to such date
(determined on a consolidated basis without duplication in accordance with
GAAP) minus (ii) the aggregate amount paid by the Borrowers and their
Subsidiaries in cash in respect of the current portion of all income taxes for
such period minus (iii) the aggregate amount of all Non-Financed Capital
Expenditures of the Borrower and their Subsidiaries during such period, to (b)
the sum for the Borrowers and their Subsidiaries (determined on a consolidated
basis without duplication in accordance with GAAP), of (i) the aggregate amount
of Interest Expense for such period, (ii) the aggregate amount of regularly
scheduled payments of principal in respect of Indebtedness for borrowed money
(including the principal component of any payments in respect of Capital Lease
Obligations) paid or required to be paid during such period, (iii) the
aggregate amount of cash payments in respect of Earn Out Obligations paid or
required to be paid during such period and (iv) the aggregate amount of cash
dividends and distributions paid by the Borrowers and their Subsidiaries during
such period; provided, however, that for the Fiscal Quarter ending
September 30, 2003 and for any fiscal period thereafter which includes such
Fiscal Quarter, the Borrowers shall be permitted to add to the numerator of
such ratio an amount equal to the lesser of (x) the actual amount of non-cash
losses resulting from accounts receivable reserves and/or write-offs recognized
by the Borrowers during such Fiscal Quarter with respect to certain
uncollectible receivables of the Borrowers and (y) $7,000,000.”

 

4.             Amendment to Definition of
Letter of Credit Sublimit.  The
definition of Letter of Credit Sublimit set forth in Section 1.01 is hereby
amended by deleting such subsection in its entirety and replacing it with the
following:

 

“Letter of Credit
Sublimit” means $2,500,000.”

 

5.             Amendment to Definition of
Revolving Credit Commitments.  The
definition of Revolving Credit Commitments is hereby amended by deleting such
definition in its entirety and replacing it with the following:

 

“Revolving Credit
Commitments” means, the commitments of the Lenders to make Revolving Credit
Loans to the Borrowers as in effect from time to time hereunder.  The aggregate amount of Revolving Credit
Commitments shall initially equal $20,000,000 and may be reduced pursuant to §
2.10.”

 

6.             Amendment to Schedule 2.01(a).  The amended Schedule 2.01(a) attached
hereto is hereby incorporated into the Credit Agreement as of the date hereof
and each reference in the Credit Agreement to such Schedule shall be deemed to
refer to such Schedule attached hereto on and after the date hereof.

 

7.             Amendment to Section 7.11.  Section 7.11 of the Credit Agreement is
hereby amended by deleting such section in its entirety and replacing it with
the following:

 

“Section 7.11       Field Audits.  The Borrowers will permit the Agent to
conduct field audit examinations of, among other things, the Borrowers’ and
their Subsidiaries’ assets, liabilities, books, records, billing and collection
processes and management information systems once each Fiscal Year; provided that
(i) in the event that the sum of (x) the average outstanding principal amount
of all Loans plus (y) the average Letter of Credit Exposure

 

2

 

exceeds $5,000,000 for a
period of 30 consecutive days, the Agent shall thereafter have the right to
conduct field audit examinations twice each Fiscal Year; and (ii) the Agent
shall have the right to conduct field audit examinations at times and with such
frequencies as the Agent deems appropriate upon the occurrence and during the
continuance of a Default.  Each Lender
shall have the right to participate, in a manner reasonably acceptable to such
Lender, in such field audit examinations. 
The Borrowers will reimburse the Agent for the expense of each field
audit examination at the Agent’s standard per diem rate per person, plus
out-of-pocket expenses.  In connection
with such field audits, the Borrowers will permit the Agent to make test
verifications of the Accounts with the Borrowers’ and their Subsidiaries’ customers.”

 

8.             Amendment to Section 8.04.  Section 8.04 of the Credit Agreement is
hereby amended by deleting such Section in its entirety and replacing it with
the following:

 

“Section 8.04.        Dividends and Stock Repurchases.  Declare or pay any dividends, purchase,
redeem, retire or otherwise acquire for value any of its capital stock now or
hereafter outstanding, or make any distribution of assets to its stockholders
as such whether in cash, assets or in obligations of the Borrowers, or allocate
or otherwise set apart any sum for the payment of any dividend or distribution
on, or for the purchase, redemption or retirement of any shares of its capital
stock, or make any other distribution by reduction of capital or otherwise in
respect of any shares of its capital stock or permit any Subsidiary to purchase
or otherwise acquire for value any stock of the Borrowers or another
Subsidiary, except that:  (a) Option
Care may declare and deliver dividends and make distributions payable solely in
common stock of Option Care; (b) so long as no Default or Event of Default
shall have occurred and be continuing and no Default or Event of Default shall
be caused thereby, Option Care may declare and pay cash dividends and make cash
distributions; provided that the aggregate cash paid by Option Care
during any fiscal year in respect of dividends and distributions shall not
exceed $2,500,000; (c) Option Care may purchase or otherwise acquire shares of
its capital stock for cash from employees or directors in connection with the termination
of their employment or affiliation with Option Care and pursuant to employee
stock redemption plans; provided that the aggregate cash consideration
paid by Option Care for all such shares does not exceed $500,000 during any
fiscal year; and (d) Option Care may purchase, redeem or otherwise acquire
shares of its capital stock from stockholders (collectively, “Share
Repurchases”); provided that (i) the aggregate cash consideration
paid by Option Care for all Share Repurchases after the Effective Date shall
not exceed $8,000,000, (ii) notwithstanding anything set forth in Section 9.03
to the contrary, after giving effect to each Share Repurchase, the Borrowers
shall have Collateral Availability of not less than $2,000,000 and (iii) after
giving effect to each Share Repurchase, the Total Leverage Ratio of the
Borrowers shall not exceed 2.25 to 1.00 on a proforma basis for the twelve
months most recently ended.  In
addition, if, as a result of any proposed Share Repurchase, the aggregate cash
consideration paid by Option Care for all Share Repurchases after the Effective
Date shall exceed either (x) $4,000,000 or (y) $6,500,000, the Borrowers shall
deliver to the Agent not earlier than three (3) Banking Days prior to the
consummation of such Share Repurchase, a certificate of the CFO of Option Care
in form reasonably satisfactory to the Agent confirming compliance with the
conditions set forth in clauses (ii) and (iii) of clause (d) of this Section
8.04.”

 

3

 

9.             Amendment to Section 9.03.  Section 9.03 of the Credit Agreement is
hereby amended by deleting such Section in its entirety and replacing it with
the following:

 

“Section 9.03         Minimum Collateral Availability.  The Borrowers shall not permit the Collateral
Availability at any time to be less than $2,000,000.”

 

10.           Special Representations and
Warranties with respect to the Clinical Resource Sale.  The Borrowers hereby represent and warrant
to the Agent and each Lender that (i) the assets sold by Option Care
Enterprises, Inc. in connection with the Clinical Resource Sale constitute all
of the assets used by Clinical Resource Network in the conduct of its business
prior to the Clinical Resource Sale; (ii) the principal amount of the Clinical
Resource Promissory Note represents the total amount of the Borrowers’
investment in Clinical Resource Network and no revenues or Accounts were
generated by Clinical Resource Network in the conduct of its business; (iii) no
Accounts or inventory were sold, leased, assigned or otherwise transferred by
Option Care Enterprises, Inc. in connection with the Clinical Resource Sale and
(iv) after giving effect to the Clinical Resource Sale, Clinical Resource
Network no longer conducts business and does not own or hold any property or
assets.

 

11.           Waiver with respect to Dissolution
of Clinical Resource Network, Inc. 
The Borrowers have informed the Agent that they wish to dissolve
Clinical Resource Network.  Based upon
the representations set forth in Section 10 hereof, the Agent and the Lenders
hereby waive the provisions of Sections 8.02 and 10.01(e)(3) to the extent
necessary to permit the Borrowers to dissolve Clinical Resource Network.

 

12.           Effectiveness.  This Amendment shall be not deemed effective
until the Agent receives (i) the Webster Assignment duly executed by Webster
Bank and (ii) duly executed copies of this Amendment from the Lenders and the
Borrowers.

 

13.           Assignment of Clinical Resource
Promissory Note.  Within 30 days
after the effective date of this Amendment, Option Care Enterprises, Inc. shall
deliver to the Agent an assignment of the Clinical Resource Promissory Note to
the Agent for the benefit of the Lenders in form and substance satisfactory to
the Agent.  Such assignment shall
provide that all payments of principal and interest payable to or received by
Option Care Enterprises, Inc. under the Clinical Resource Promissory Note shall
be paid directly to the Agent for the benefit of the Lenders.

 

14.           LaSalle Blocked Account Agreement.  Within 30 days after the effective date of
this Amendment, the Borrowers, LaSalle Bank National Association and the Agent
shall execute and deliver a tri-party blocked account agreement in form and
substance satisfactory to the Agent with respect to the bank account maintained
by the Borrowers at LaSalle Bank National Association.

 

15.           Representations and Warranties;
Events of Default.  Each Borrower
hereby represents and warrants to the Agent and each Lender that to such
Borrower’s knowledge:  (i) except as
otherwise disclosed in the schedules attached to the Credit Agreement, all of
the representations and warranties of the Borrowers set forth in the Credit
Agreement are true and correct in all material respects with the same force and
effect as if made on and as of the date of this Amendment; (ii) there exists no
Default or Event of Default; and (iii) no material litigation proceedings or
investigations relating to any of the Borrowers are pending.

 

16.           Miscellaneous.

 

(a)           The Credit Agreement, as amended by
this Amendment, and each of the other Facility Documents shall remain in full
force and effect and are hereby ratified and confirmed in all respects.  The

 

4

 

execution,
delivery and effectiveness of this Amendment shall not operate as a waiver of
any right, power or remedy of the Agent or the Lenders under the Facility
Documents, nor constitute a waiver of any provision of the Facility Documents
except as specifically set forth herein.

 

(b)           Each of the Borrowers hereby
ratifies, affirms, acknowledges and agrees that the Credit Agreement and the
other Facility Documents represent the valid, enforceable and collectible
obligations of each Borrower, and each Borrower further acknowledges that there
are no existing claims, defenses, personal or otherwise, or rights of setoff
whatsoever with respect to the Credit Agreement or any of the other Facility
Documents.  Each Borrower hereby agrees
that this Amendment in no way acts as a release or relinquishment of the Liens
securing the Obligations, and such Liens are hereby ratified and confirmed by
each Borrower in all respects.

 

(c)           THIS AMENDMENT SHALL BE GOVERNED BY,
AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW
YORK.

 

5

 

IN WITNESS WHEREOF, the parties have caused
this Fifth Amendment to Credit and Security Agreement to be executed and
delivered by their proper and duly authorized officers as of the date first
above written.  

 

BORROWERS

 

OPTION
CARE, INC., a Delaware corporation,

OPTION CARE, INC., a California corporation

MANAGEMENT BY INFORMATION, INC.

OPTION CARE HOME HEALTH OF CALIFORNIA, INC.

OPTION CARE OF OKLAHOMA, INC.

OPTIONET, INC.

HOME HEALTH OF OPTION CARE, INC.

OPTION CARE ENTERPRISES, INC., a
   
Delaware corporation

OPTION CARE HOSPICE, INC. 

OPTION CARE ENTERPRISES, INC., a
    Pennsylvania corporation

OPTION CARE OF DENVER, INC.

OPTION HOME HEALTH, INC.

OPTIONMED, INC.

EXCEL HEALTHCARE, L.L.C.

REHAB OPTIONS, INC.

NORTH COUNTY HOME I.V., INC.

SPRINGVILLE PHARMACY INFUSION
    THERAPY, INC.

INFUSION SPECIALTIES, INC.

OPTION CARE OF NEW YORK, INC.

OPTION CARE ENTERPRISES OF NEW
    YORK, INC.

 

 

	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  	
  Richard M. Smith

  
	
   

  	
  Title:

  	
  President and Chief Operating Officer

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  	
  Joseph P. Bonaccorsi

  
	
   

  	
  Title:

  	
  Secretary

  

 

 

[Signature Page to Fifth Amendment to

Credit and Security Agreement]

 

 

	
   

  	
  OPTION CARE HOME HEALTH, L.L.C.

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  	
  Richard
  M. Smith

  
	
   

  	
  Title:

  	
  President
  and Chief Operating Officer

  
	
   

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  	
  Joseph
  P. Bonaccorsi

  
	
   

  	
  Title:

  	
  Secretary

  
	
   

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By

  	
  Option
  Care Enterprises, Inc., a member

  
	
   

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  	
  Richard M. Smith

  
	
   

  	
  Title:

  	
  President and Chief Operating Officer

  
	
   

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  	
  Joseph P. Bonaccorsi

  
	
   

  	
  Title:

  	
  Secretary

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  CLINICAL
  RESOURCE NETWORK, INC.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By: 

  	
   

  	
   

  
	
   

  	
  Name:

  	
  Gail Adinamis

  
	
   

  	
  Title:

  	
  President

  
	
   

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By: 

  	
   

  	
   

  
	
   

  	
  Name:

  	
  Joseph Bonaccorsi

  
	
   

  	
  Title:

  	
  Secretary

  
												

 

[Signature Page to Fifth Amendment to

Credit and Security Agreement]

 

 

	
   

  	
  AGENT AND LENDER:

  
	
   

  	
   

  
	
   

  	
  JPMORGAN CHASE
  BANK, in its capacities as Administrative and Collateral Agent and Lender

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  Name:

  
	
   

  	
   

  
	
   

  	
  Title:

  

 

[Signature Page to Fifth Amendment to

Credit and Security Agreement]

 

 

	
   

  	
  ADDITIONAL LENDER:

  
	
   

  	
   

  
	
   

  	
  LASALLE BANK
  NATIONAL ASSOCIATION

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  Name:

  
	
   

  	
   

  
	
   

  	
  Title:

  

 

[Signature Page to Fifth Amendment to

Credit and Security Agreement]

 

 

Schedule 2.01(a)

 

to

 

OPTION
CARE, INC.

 

Credit
Agreement

 

List
of Lenders and Commitments

 

	
  Name of Lender

  	
   

  	
  Revolving
  Credit

  Commitment

  Amount

  	
   

  	
  Revolving
  Credit

  Commitment

  Percentage

  	
   

  
	
  JPMorgan Chase Bank

  	
   

  	
  13,333,333.34

  	
   

  	
  66.6666667

  	
  %

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LaSalle Bank National Association

  	
   

  	
  6,666,666.66

  	
   

  	
  33.3333333

  	
  %

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Total

  	
   

  	
  $

  	
  20,000,000

  	
   

  	
  100.0000000

  	
  %

  
							

 

10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}]]